UK-based Pharma giant GSK plc reported its Q2 earnings earlier today. GSK plc exceeded Q2 2024 expectations with revenue up 13%, operating profit up 18%, and EPS up 17%. GSK upgraded full-year ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

Summary. GSK's stock price has dropped by 6.7% since July, but still outperformed the S&P 500 and the healthcare sector. This could change, as the company's Q3 2023 earnings are expected to show ...

GSK plc (NYSE:GSK) is one of the best cheap stocks under $50 to buy now. On July 15, BofA analyst Sachin Jain maintained a ...

In May, biotech iTeos Therapeutics decided to close down after being abandoned by GSK over the disappointing mid-stage ...

GSK and S&P 500 Performance During 2007-08 Crisis. GSK stock declined from $53 in September 2007 (pre-crisis peak) to around $28 in March 2009, as the markets bottomed out, implying it lost 48% of ...

GSK settles U.S. Zantac lawsuit, avoiding trial. Confidential settlements reinforce commitment to legal efficiency.

The most recent trading session ended with GSK (GSK) standing at $42.79, reflecting a -0.09% shift from the previouse trading day's closing. This move was narrower than the S&P 500's daily loss of ...

Why GSK Stock Rocketed Nearly 6% ... a performance that easily eclipsed the 0.7% rise of the ... our expert team of analysts issues a “Double Down” stock recommendation for companies that they ...

Additionally, GSK has a PEG Ratio of 1.3 and a Price/Cash Flow ratio of 6.8X. Value investors should also note GSK's Price/Sales ratio of 1.9X. A company's earnings performance is important for ...

Additionally, GSK has a PEG Ratio of 1.2 and a Price/Cash Flow ratio of 7.3X. Value investors should also note GSK's Price/Sales ratio of 2X. A company's earnings performance is important for ...